Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) insider Ariel Hurley sold 1,819 shares of the company's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94. Following the transaction, the insider now owns 14,967 shares of the company's stock, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Blueprint Medicines Price Performance

Blueprint Medicines stock traded up $2.20 during midday trading on Monday, reaching $95.39. 472,107 shares of the company were exchanged, compared to its average volume of 686,052. The firm's 50-day simple moving average is $92.15 and its 200-day simple moving average is $97.39. Blueprint Medicines Co. has a 1 year low of $72.24 and a 1 year high of $121.90. The company has a market capitalization of $6.06 billion, a price-to-earnings ratio of -45.21 and a beta of 0.59. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company's quarterly revenue was up 126.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.20) earnings per share. On average, analysts anticipate that Blueprint Medicines Co. will post -3.68 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of BPMC. Wellington Management Group LLP grew its position in shares of Blueprint Medicines by 22.5% in the third quarter. Wellington Management Group LLP now owns 3,964,610 shares of the biotechnology company's stock valued at $366,726,000 after purchasing an additional 729,055 shares during the period. State Street Corp grew its holdings in Blueprint Medicines by 16.2% in the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after buying an additional 385,818 shares during the period. Geode Capital Management LLC increased its stake in shares of Blueprint Medicines by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,480,187 shares of the biotechnology company's stock valued at $136,942,000 after acquiring an additional 20,703 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Blueprint Medicines by 4.2% during the 2nd quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company's stock worth $86,519,000 after acquiring an additional 32,600 shares during the period. Finally, Millennium Management LLC lifted its holdings in shares of Blueprint Medicines by 540.0% during the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company's stock worth $67,646,000 after acquiring an additional 529,566 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BPMC shares. JPMorgan Chase & Co. began coverage on Blueprint Medicines in a report on Thursday, November 14th. They issued an "overweight" rating and a $126.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. JMP Securities restated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Monday, December 9th. Wedbush reiterated an "outperform" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research note on Thursday, November 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Friday, November 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $122.11.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.